AEROVATE THERAPEUTICS
Aerovate Therapeutics is a biotechnology company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's program is a potentially disease-modifying drug, AV-101, for people who suffer from pulmonary arterial hypertension (PAH). AV-101 is a proprietary inhaled dry powder formulation of the drug imatinib that delivers this medicine directly to diseased lung tissues while reducing systemic adverse side effects. The company was founded and incubated by RA Capital Management, a multi-stage investment manager focused on healthcare and life sciences.
AEROVATE THERAPEUTICS
Social Links:
Industry:
Biotechnology Life Science Medical
Founded:
2019-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.aerovatetx.com
Total Employee:
11+
Status:
Active
Contact:
+1 617 778 2494
Email Addresses:
[email protected]
Total Funding:
72.6 M USD
Technology used in webpage:
IPv6 COVID-19 Akamai Hosted
Similar Organizations
Ajax Therapeutics
Ajax Therapeutics is a biotechnology company developing therapies to target cytokine signaling pathways that drive hematologic malignancies.
Ardeagen
Ardeagen is a biotechnology company that conducts research and development of drugs and antibodies for cancer.
Atalanta Therapeutics
Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases.
Electra Therapeutics
Electra Therapeutics is a clinical stage biotechnology company developing therapies for cancer and other immunological diseases.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Larimar Therapeutics
Larimar Therapeutics is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Surveyor Capital
Surveyor Capital investment in Series A - Aerovate Therapeutics
Atlas Venture
Atlas Venture investment in Series A - Aerovate Therapeutics
Cormorant Asset Management
Cormorant Asset Management investment in Series A - Aerovate Therapeutics
Sofinnova Investments
Sofinnova Investments investment in Series A - Aerovate Therapeutics
OUP (Osage University Partners)
OUP (Osage University Partners) investment in Series A - Aerovate Therapeutics
RA Capital Management
RA Capital Management investment in Seed Round - Aerovate Therapeutics
Official Site Inspections
http://www.aerovatetx.com Semrush global rank: 2.88 M Semrush visits lastest month: 5.68 K
- Host name: 241.121.134.34.bc.googleusercontent.com
- IP address: 34.134.121.241
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Aerovate Therapeutics"
About Us - Aerovate Therapeutics
With deep expertise that spans drug development through to commercialization, Aerovate's team is developing meaningful therapies for cardiopulmonary diseases.See details»
Aerovate Therapeutics - Crunchbase Company Profile & Funding
Aerovate Therapeutics is a biotechnology company focused on developing drugs for rare cardiopulmonary disease.See details»
Aerovate Therapeutics, Inc. - LinkedIn
Aerovate Therapeutics, Inc. | 4,169 followers on LinkedIn. Aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with ...See details»
Investors - Aerovate Therapeutics
Aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Our initial focus …See details»
Aerovate Therapeutics Board of Directors Appoints Habib Dable as …
WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs …See details»
Aerovate Therapeutics Appoints Habib Dable To Its Board of …
About Aerovate Therapeutics, Inc. Aerovate is a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare …See details»
Aerovate Therapeutics, Inc. (AVTE) Company Profile & Overview
Jun 30, 2021 Company profile for Aerovate Therapeutics, Inc. (AVTE) with a description, list of executives, contact details and other key facts.See details»
Aerovate Therapeutics Announces Simultaneous Completion of …
“The completion of enrollment in the Phase 2b portion of the trial marks an exciting milestone for Aerovate and for people living with PAH,” said Tim Noyes, Chief Executive Officer at Aerovate ...See details»
Aerovate Therapeutics - ZoomInfo
May 15, 2024 View Aerovate Therapeutics (www.aerovatetx.com) location in Massachusetts, United States , revenue, industry and description. Find related and similar companies as well …See details»
Aerovate Therapeutics Appoints Habib Dable To Its Board of …
Jul 11, 2023 Mr. Dable is currently a part-time Venture Partner at RA Capital Management, L.P., and previously served on the Board of Directors of the Biotechnology Innovation Organization …See details»
Press Release - ir.aerovatetx.com
AV-101 is a Proprietary Inhaled Version of Imatinib, Which Has Proven Efficacy Treating PAH; Aerovate Was Founded and Seeded by RA Capital Management; Series A is Led by …See details»
Programs - Aerovate Therapeutics
May 16, 2024 Aerovate’s lead program, AV-101, a dry powder inhaled formulation of imatinib, directly targets the proliferative cells in the blood vessels of the lungs.See details»
Aerovate Therapeutics Announces First Quarter Financial ... - Nasdaq
May 13, 2024 --Aerovate Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare …See details»
Aerovate Therapeutics to Present at Jefferies Global Healthcare ...
WALTHAM, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that …See details»
Aerovate Therapeutics Presents Baseline Data from the Phase 2b …
May 21, 2024 The 202 adult patients in the Phase 2b portion of IMPAHCT are roughly split between World Health Organization functional classes II and III, with approximately 57% of …See details»
Aerovate Therapeutics Presents Baseline Data from the Phase
May 21, 2024 The 202 adult patients in the Phase 2b portion of IMPAHCT are roughly split between World Health Organization functional classes II and III, with approximately 57% of …See details»
Press Release - Aerovate Therapeutics, Inc.
BOSTON, July 02, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully …See details»
Aerovate Therapeutics to Present Patient Baseline Characteristics …
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs …See details»
Aerovate Therapeutics Announces Pricing of Upsized Initial Public ...
BOSTON, June 29, 2021 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully …See details»